Status:
COMPLETED
Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
Lead Sponsor:
Bayer
Conditions:
Breast Neoplasms
Prostatic Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers. The adherence to medications has ...
Eligibility Criteria
Inclusion
- Diagnosis of breast cancer, prostate cancer, multiple myeloma and other skeletal events causing tumors
- Bone metastases
- Therapy with clodronate (1600 mg per day, 800 mg tablets) according to SmPC (Summary of Product Characteristics) Bonefos.
- By agreeing to usage of patients diaries and goodwill with accounting of tablets
Exclusion
- According to SmPC (Summary of Product Characteristics) Bonefos.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT01198457
Start Date
January 1 2009
End Date
June 1 2010
Last Update
September 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Czechia